Respiratory Health

Like with most organ-related health issues, what tends to go wrong with breathing isn’t about the lungs themselves. It’s about how you use them, how the air around them got that way, and whether anyone caught the underlying pattern before it became a diagnosis.

This page attempts to map out where breathing physiology crosses into medicine. We’ll be covering key respiratory health issues like asthma, COPD, sleep apnea, breathing pattern disorders, and air quality problems. If you want techniques to use right now, the Breathwork Cheat Sheet covers that. If you want an explanation of how breathing actually works, Breathwork Basics covers that. Here, we’re looking at what happens when the system breaks down, what the medical world does and doesn’t do well about it, and what we as individuals can do.

A note before we start: this page is meant to make you a more informed patient and a more capable advocate for your own care rather than as a substitute for medical evaluation. The framework here is about understanding what they’re telling you and what they might be missing. Avoid dogma and polarised thought. 

The Physiology

Most respiratory dysfunction comes back to two interconnected systems: how oxygen and carbon dioxide move between blood and tissue, and how breathing patterns either support or sabotage that movement. Both are well-mapped. Neither is well-known outside specialist medicine.

The Bohr and Haldane Effects

Christian Bohr’s 1904 paper described what’s now considered foundational respiratory physiology: hemoglobin’s affinity for oxygen depends on local CO₂ and pH conditions. When CO₂ is high in tissues (like in actively working muscle), hemoglobin shifts to a “tense” state and releases oxygen where it’s needed. When CO₂ is low (the situation produced by chronic overbreathing), hemoglobin holds onto oxygen and delivery to the tissue drops.

This is the mechanism behind one of the most counterintuitive findings in breathing science: breathing more does not necessarily deliver more oxygen. Often the opposite. Hyperventilation produces hypocapnia (low CO₂) and respiratory alkalosis, which constricts blood vessels, including those in the brain. The dizziness, tingling, and brain fog that come with chronic overbreathing are from cerebral vasoconstriction caused by too much air.

The Haldane effect is the complementary mechanism. Deoxygenated hemoglobin acts as a more efficient proton acceptor, allowing it to bind more CO₂ for transport from tissues to lungs. As blood reaches the lungs and oxygen binds, CO₂ is displaced and exhaled. The two effects are coupled: the body’s gas exchange depends on a coordinated dance between O₂ and CO₂ that breaks down when breathing patterns are dysfunctional.

The clinical implication is the one most popular wellness frameworks miss: CO₂ tolerance, not maximum lung capacity, is the practical limit on respiratory efficiency for most people. This is the foundation that the Buteyko tradition built its clinical work on, and it’s why slow, controlled breathing tends to outperform forceful breathing for almost every health outcome that’s been measured.

Dysfunctional Breathing as a Clinical Category

Dysfunctional breathing (DB) is a recognized clinical condition that most patients have never heard of. Partly because primary care training rarely covers it, partly because it doesn’t have a billing code that drives screening, and partly because its symptoms are nonspecific enough that it gets shoved into other diagnoses.

Roughly 10% of adults seen in primary care show signs of dysfunctional breathing patterns. In patients diagnosed with asthma, the figure rises to about 30%. Meaning that one in three asthma patients may have a breathing pattern problem either alongside or instead of true asthma. In severe cases, the breathing pattern is the problem, and the asthma diagnosis is wrong.

The clinical taxonomy, developed by researchers including Boulding and colleagues at the University of Manchester, identifies four main patterns:

• Hyperventilation syndrome: minute ventilation exceeding metabolic need, producing hypocapnia, respiratory alkalosis, and the dizziness/tingling/panic cluster
• Periodic deep sighing: frequent sighs (more than 2 per 15 minutes at rest), often with chest tightness and a feeling of inadequate breath
• Thoracic-dominant breathing: excessive upper-chest movement with minimal diaphragm engagement, producing neck and shoulder pain alongside the respiratory symptoms
• Forced abdominal expiration: overuse of abdominal muscles to actively push air out, producing labored breathing even at rest

The standard screening tool is the Nijmegen Questionnaire, developed by Dutch researchers van Dixhoorn and Folgering. It’s a 16-item instrument that takes about three minutes and screens for dysfunctional breathing across three symptom clusters: shortness of breath, peripheral tetany (tingling, numbness, dizziness), and central tetany (palpitations, tension, anxiety). If any of those clusters resonate with your daily experience, the questionnaire is worth taking. Most physiotherapists trained in respiratory work can administer and interpret it, and several validated versions are available online.

The leverage in catching dysfunctional breathing is significant. Properly identified, most patterns respond to breathing retraining within weeks to months. The protocols sit in Breathwork Basics and the Breathwork Cheat Sheet, particularly the Buteyko-tradition material.

The Major Respiratory Conditions

Asthma

Asthma affects roughly 8% of adults and 11% of children in developed countries, and the conventional management story has been stable for decades: bronchodilators for acute symptoms, inhaled corticosteroids for maintenance, escalating to combination therapies and biologics for severe cases. This works for many patients, but it also obscures the population whose problem isn’t really airway hyperreactivity.

The 30% dysfunctional-breathing-in-asthma figure has been one of respiratory medicine’s quietly disturbing findings. A meaningful percentage of people diagnosed with poorly controlled asthma actually have dysfunctional breathing patterns that don’t respond to bronchodilators because the bronchoconstriction isn’t really there. What’s happening is hypocapnia from chronic overbreathing, perceived as breathlessness. The escalation cycle is predictable: rescue inhaler use rises, controller medication doses increase, the patient is described as “poorly controlled,” and more medication gets added.

Inhaler manufacturers (GSK, AstraZeneca, others) have minimal incentive to fund research into breathing-pattern interventions that might substitute for their products. Government and academic funding fill part of the gap, but there is a glaringly wide asymmetry. Multiple randomized controlled trials (Bowler in 1998 (Australia), Cowie in 2008 (Canada), and others) have shown that the Buteyko-method breathing reduces rescue medication use by approximately 90% and inhaled steroid use by approximately 49% over three months in asthma populations, without a significant change in objective lung function. These results come from the Medical Journal of Australia and Respiratory Medicine. The 2020 Cochrane review on breathing exercises for asthma concluded that breathing interventions produce real benefits in symptom control and quality of life.

Despite this, breathing retraining isn’t routinely offered in most asthma management. Mainly due to the fact that the medical education is shaped by what’s reimbursable, what’s pharmaceutically supported, and what fits into a 15-minute appointment.

If you have asthma (particularly if you’ve been told it’s “poorly controlled” despite medication compliance) three questions are worth asking your clinician:

1. Has anyone screened you for dysfunctional breathing patterns? (Ask about the Nijmegen Questionnaire)
2. What’s your peak flow and FEV1 actually doing during your symptom flares? If they’re within normal range when you feel breathless, the breathlessness may not be coming from bronchoconstriction.
3. Is breathing retraining something they can refer you for? Respiratory physiotherapists trained in Buteyko-tradition or pattern-disorder work exist; finding one near you may take effort, but can be worth it.

The breathing protocols themselves sit in the Cheat Sheet. The clinical caveat: never stop or reduce asthma medication without your clinician’s involvement. The goal of breathing retraining is to make the system more efficient and resilient over time.

Chronic Obstructive Pulmonary Disease (COPD)

COPD is largely a disease of cumulative damage. Primarily from smoking, secondarily from long-term air pollution exposure. The structural lung damage doesn’t reverse, but the functional capacity of the system can be substantially improved through pulmonary rehabilitation, which is one of the more underused interventions in respiratory medicine.

Pursed-lip breathing, covered in detail in the Breathwork Cheat Sheet, is the most clinically validated breathing technique on the entire HOM site. It’s standard in pulmonary rehabilitation programs because it works through clear physiology: the back-pressure from pursed lips keeps small airways open during exhalation, preventing the air-trapping that drives COPD breathlessness. Meta-analyses, including Mayer et al. 2018 in Physiotherapy have established that it reduces breathlessness, slows respiratory rate, and improves oxygen saturation during exertion.

Diaphragmatic breathing training, inspiratory muscle training using resistance devices, and exercise tolerance work all have substantial evidence bases in COPD populations. The whole field of pulmonary rehabilitation (multidisciplinary programs combining exercise, breathing training, education, and psychosocial support) has been shown in multiple Cochrane reviews to improve quality of life, reduce hospitalization rates, and extend functional capacity in COPD.

Sleep Apnea

Obstructive sleep apnea (OSA) is one of the most consequential conditions in respiratory medicine and one of the most underdiagnosed. Estimates suggest that roughly a third of adults with moderate-to-severe OSA are undiagnosed, with the rate substantially higher in women and lean individuals who don’t fit the stereotypical risk profile. The downstream consequences are serious: cardiovascular disease, hypertension, type 2 diabetes, cognitive decline, mood disorders, and increased mortality.

The condition is mechanically straightforward: repetitive collapse of the upper airway during sleep, producing brief breath cessations and oxygen desaturation, fragmenting sleep architecture and producing chronic intermittent hypoxia. Stanford sleep medicine pioneer Christian Guilleminault did much of the foundational research on OSA and on the broader category of upper airway resistance syndrome (UARS), which doesn’t show up on standard polysomnography but produces similar fragmentation through subtler mechanisms.

Three things worth knowing about OSA that the popular discourse doesn’t always surface:

The diagnosis is often missed. Standard screening (the STOP-BANG questionnaire) catches obvious cases but misses many presentations, particularly UARS-pattern breathing in women. If you wake unrefreshed despite adequate sleep duration, snore (or your partner reports gasping or pauses), have unexplained morning headaches, or have unexplained blood pressure that’s hard to control, sleep apnea is worth investigating.

Self-screening with consumer pulse oximetry is increasingly viable. Continuous overnight pulse oximetry (devices like Wellue O2Ring, or some Garmin and Apple Watch products) can capture oxygen desaturation patterns that strongly suggest apnea. Formal sleep medicine evaluation requires polysomnography or a validated home sleep test, but it’s a reasonable first-pass tool, particularly given the cost and access barriers to formal sleep studies.

The CPAP industry has its own complications. CPAP remains the gold-standard treatment for moderate-to-severe OSA, and it works, but the device industry isn’t without problems. The 2021 Philips DreamStation recall, involving polyurethane foam degradation that may have exposed millions of patients to potentially carcinogenic compounds, is an extraordinary case of regulatory and manufacturing failure that’s still working through litigation. More broadly, the SAVE trial published in NEJM in 2016 raised legitimate questions about whether CPAP reduces cardiovascular events in patients with moderate-to-severe OSA who lack daytime sleepiness. The answer was no, which complicates the “everyone with OSA needs CPAP” framing. This isn’t a reason to refuse CPAP if it’s appropriate. It’s a reason to be a more informed participant in the decision.

For mild OSA specifically, alternatives include positional therapy, oral mandibular advancement appliances, weight management when relevant, addressing nasal obstruction, and orofacial myofunctional therapy. All of which are covered in more depth on the Nasal Breathing page. Mouth taping has modest evidence in mild OSA populations but is dangerous in moderate-to-severe disease; the contraindications are detailed in the Cheat Sheet.

Allergic Rhinitis and Chronic Congestion

Chronic nasal obstruction drives mouth breathing, which drives the cascade of downstream effects covered in detail on the Nasal Breathing page, disrupted sleep, altered facial development in children (Harvold’s foundational rhesus monkey work and Guilleminault’s pediatric research), reduced nitric oxide production, and compromised immune function in the upper airway.

Treatment hierarchy: identify and reduce allergen exposure where possible, use saline nasal rinses (the evidence is solid), consider a trial of intranasal corticosteroids for persistent symptoms, see an ENT or allergy specialist if symptoms persist despite first-line management. Chronic mouth breathing in adults that doesn’t resolve with medical management is worth investigating for structural causes (deviated septum, turbinate hypertrophy, nasal valve collapse) that may benefit from surgical intervention.

Air Quality and Lung Function

The full treatment of indoor and outdoor air quality, including the building science, the gas-stove and combustion research, the PM2.5 mortality data, and the practical interventions, lives on the Environment page.

The respiratory-specific summary:

Air pollution is one of the largest preventable mortality factors globally. The World Health Organization estimates that ambient air pollution causes approximately 4 million premature deaths per year worldwide, with PM2.5 (fine particulate matter) being the dominant pollutant in terms of population health burden. The mechanism in respiratory disease is well-established: PM2.5 penetrates deep into lung tissue, triggers inflammation, accelerates COPD progression, increases asthma exacerbations, and contributes to lung cancer risk.

Indoor air quality is often worse than outdoor air, particularly in modern energy-efficient buildings. Joe Allen’s research at Harvard’s Healthy Buildings program has been some of the cleanest work on this, including the 2016 Environmental Health Perspectives paper showing that elevated indoor CO2 levels (common in poorly ventilated meeting rooms and bedrooms) measurably impair cognitive performance. The gas stove NO2 question, which surfaced in mainstream coverage in 2023, has substantial epidemiological support; gas combustion in unventilated kitchens produces NO2 levels that would be illegal outdoors and is associated with childhood asthma development.

The respiratory-relevant practical moves: ventilate enclosed spaces, particularly kitchens and bedrooms; consider HEPA filtration if you live in a high-pollution area or near major roads; check AQI before outdoor exercise on bad-air days; if you cook with gas, run the range hood. The Environment page has the deeper treatment.

Lung Function as a Mortality Predictor

The strongest single-variable predictor of all-cause mortality in adults isn’t cholesterol, blood pressure, or even diabetes status. It’s cardiorespiratory fitness. Usually measured as VO2 max. The 2018 paper by Mandsager and colleagues at the Cleveland Clinic, published in JAMA Network Open, examined 122,000 patients undergoing exercise treadmill testing and found that low cardiorespiratory fitness was associated with mortality risk comparable in magnitude to smoking, and that the relationship was dose-dependent across the entire fitness spectrum. There was no upper plateau. Elite-level fitness produced the lowest mortality, with no evidence that being too fit was a problem.

This is the kind of finding that should be much better known than it is. The entire popular wellness industry tends to focus on metrics that move easily, like body weight, cholesterol numbers, and sleep scores. VO2 max is harder to change, takes longer to change, and predicts more.

Lung function specifically (Forced Vital Capacity and FEV1) is also independently associated with mortality, but the relationship is more confounded by smoking history, occupational exposure, and other factors. The cleaner story is that respiratory and cardiovascular fitness travel together, and training one supports the other.

Inspiratory Muscle Training

Inspiratory muscle training (IMT) is the practice of using resistance devices. Typically, a small handheld unit that creates resistance to inhalation to strengthen the diaphragm and accessory respiratory muscles. The evidence base in COPD populations is solid; IMT improves exercise tolerance, reduces breathlessness, and improves quality of life. The evidence in healthy populations and athletes is more variable; it appears to help in some endurance sports applications, but the magnitude isn’t large.

Practical implementation: devices like the POWERbreathe and Airofit are commercially available; protocols typically involve 30 breaths twice daily at moderate-high resistance, progressing over weeks. For COPD or other clinical respiratory conditions, this should be done within a pulmonary rehabilitation program rather than independently.

Heat and Cold

The respiratory effects of sauna and cold exposure are real and worth understanding, but the in-depth treatment lives on the Thermoregulation page. Jari Laukkanen’s Finnish work on sauna and cardiovascular mortality is the strongest evidence base; the respiratory benefits in healthy populations are likely real but more modest than the popular discourse suggests. Cold exposure has measurable effects on respiratory rate and tidal volume during the cold-shock response, and there’s ongoing research on whether deliberate cold exposure produces lasting respiratory adaptations. The work is interesting, but the popular conclusions are running ahead of the evidence in places. Mostly as a result of attention-grabbing content creation on social media, and to drive book and course sales. 

The Industry Landscape

The respiratory pharmaceutical market is significant: global asthma and COPD medications generate revenue in the tens of billions annually. The major players (GSK, AstraZeneca, Boehringer Ingelheim, others) fund substantial research, but that research is shaped by commercial incentive structures. Drugs that can be patented, prescribed, and reimbursed get funded. Interventions that can’t (breathing retraining, environmental modification, weight loss, pulmonary rehabilitation) get less attention and less implementation, even when the evidence supports them.

This isn’t a uniquely respiratory problem; it’s the structure of medical research generally. Marcia Angell’s work at the NEJM and her book The Truth About the Drug Companies, Ben Goldacre’s Bad Pharma and the AllTrials initiative he co-founded, and John Abramson’s Sickening all document the broader pattern in detail. In respiratory medicine specifically, the asthma-and-Buteyko gap and the OSA-and-CPAP industry are useful case studies for how the pattern works at the individual-condition level.

The Philips DreamStation recall is a more specific case worth knowing. From 2009 to 2021, Philips manufactured CPAP and BiPAP machines containing polyurethane foam that could degrade and release potentially carcinogenic compounds into the air patients breathed. The recall, when it finally happened in mid-2021, affected millions of devices. Internal documents released through litigation suggest the company was aware of the foam degradation issues for years before the recall. 

The implications for individual patients: be a more active participant in your own respiratory care. Ask whether your clinician has considered breathing-pattern interventions before escalating medication. Understand what your prescribed treatment is actually doing (and isn’t). Know that pulmonary rehabilitation exists and is underused. Don’t refuse evidence-based medication because a company makes money from it, but don’t accept that medication is the only available tool.

When to Get Professional Help

The hardest part of any self-directed health framework is knowing when to step out of it. A few clear indicators:

See a clinician promptly if:

• You experience sudden severe shortness of breath, particularly at rest or with chest pain
• You cough up blood
• You have a persistent cough lasting more than three weeks, especially with weight loss or night sweats
• You have wheezing that’s new or rapidly worsening
• You’re using a rescue inhaler more than twice a week
• You’re experiencing increasing breathlessness over months which is interfering with normal activities

Consider a sleep medicine evaluation if:

• Your partner reports witnessing apneas, gasping, or choking during sleep
• You have unrefreshing sleep despite adequate duration
• You have unexplained morning headaches
• You have hypertension that’s resistant to treatment
• You have unexplained fatigue, especially with the above

Consider pulmonary rehabilitation if:

• You have COPD at any stage
• You have symptomatic asthma despite medication
• You have any chronic respiratory condition limiting daily activity
• You’re recovering from a significant respiratory illness (including post-COVID syndromes)

Consider seeing an ENT or allergy specialist if:

• You have chronic nasal obstruction that doesn’t respond to first-line management
• You’ve been mouth-breathing chronically for years
• You suspect structural nasal problems (deviated septum, turbinate hypertrophy)
• Children show signs of chronic mouth breathing or sleep-disordered breathing

The throughline for all of these: the medical system has substantial gaps, and informed advocacy for your own care matters. But it also has expertise that you don’t have, and the gaps are not reasons to stay out of it. The aim is to be the kind of patient who asks better questions, not the kind who avoids the appointment.